Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase IV

Treatment

Active

Not specified

Other

HSC-MS-06-0478
OSP-24412, NCT00581425

Trial Description

Summary

A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.

Eligibility Criteria

Inclusion Criteria:

Nodular or superficial basal cell carcinoma on the skin excluding scalp or face

Exclusion Criteria:

Pregnancy

Trial Contact Information

Trial Lead Organizations/Sponsors

University of Texas Health Science Center at Houston

Stephen B Tucker, M.D.

Principal Investigator

Stephen B Tucker, M.D.		Ph: 281-773-6774
		Email: stephen.b.tucker@uth.tmc.edu

Trial Sites

U.S.A.

Texas

Houston

University of Texas Health Science Center at Houston

Stephen B Tucker, M.D. Ph: 281-773-6774

Email: stephen.b.tucker@uth.tmc.edu

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00581425
Information obtained from ClinicalTrials.gov on July 25, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.